Alere Inc. confirmed analysts’ suspicions that Abbott Laboratories Inc. is reticent about its planned $5.8 billion takeover of the embattled diagnostics company, but the deal appears to be back on track, for now.
Abbott agreed to buy Alere in February for $56 per share, a 50% premium over its pre-deal share price, citing complementary strengths in the point-of-care diagnostics market. (See [A#01160208006].)...